In order to assess whether inherited genetic variability in the mucin genes associates with the evolution of gastric cancer precursor lesions (GCPLs), we genotyped 22 tagSNPs in MUC1, MUC6 and MUC2 genes of 387 patients with GCPLs that had been followed up for 12.8 years. According to the diagnosis at recruitment and at the end of follow-up, the lesions did not change in 43.1% of the patients, regressed in 28.7% and progressed in 28.2%. Three SNPs in the 3#-moiety of MUC2 were significantly associated with a decreased risk of progression of the lesions, whereas another four SNPs, located at the 5#-moiety, were found to be significantly associated either with increased [one single-nucleotide polymorphism (SNP)] or decreased (three SNPs) probability of regression. Stratified analysis indicated that significance was maintained only in those subjects positive for Helicobacter pylori infection and in those not consuming non-steroidal anti-inflammatory drugs, which were found protective against lesion progression. Haplotype analyses indicated the presence of two haplotypes, one in each moiety of the gene, that were significantly associated with decreased risk of progression of the lesions [odds ratio (OR) 5 0.49 and 0.46; 95% confidence interval (CI) 5 0.28-0.85 and 0.25-0.86, respectively]. The 5#-end haplotype was also associated with increased probability of regression (OR 5 1.67; 95% CI 5 1.02-2.73), altogether suggesting a protective role against progression of the precancerous lesions. No significant association was found with variants in MUC1 and MUC6 genes. These results indicate, for the first time, that genetic variability in MUC2 is associated with evolution of GCPLs, especially in H.pylori infected patients, suggesting a role of this secreted mucin in gastric carcinogenesis.
Introduction
Mucins are high-molecular weight glycoproteins (50-80% O-linked oligosaccharides) synthesized by specialized epithelial cells as membrane-bound or secretory proteins that form higher-order structures (1, 2) . These glycoproteins represent the major constituents of the protective mucous layer of the gastrointestinal tract where they have a central role in maintaining epithelial homeostasis (3, 4) .
Normal gastric mucosa shows cell type-specific expression of secreted mucins MUC6, in glandular structures, and MUC5AC, in the surface epithelium. High levels of membrane-bound MUC1 have also been detected in both deep glands and superficial epithelium. This specific pattern of expression is altered in the process of neoplastic transformation of the stomach, with decreased expression of MUC6, overexpression of MUC1 and the novo expression of secreted MUC2 (5) (6) (7) . Alteration in the expression pattern of mucins may modify their epithelial functions, which in turn may influence the tumorigenicity and metastatic properties of cancer cells (8, 9) .
Gastric cancer is the result of a long multistep and multifactorial process that involves well-characterized sequential stages. The initial lesion is an inflammatory process, usually associated with Helicobacter pylori infection, that results in a chronic superficial gastritis, which progresses toward atrophic gastritis, intestinal metaplasia and, finally, to dysplasia and adenocarcinoma (10, 11) . Although H.pylori is the most important established risk factor for gastric cancer development, other environmental and lifestyle factors, as well as host genetic susceptibility, are involved in the cancer process (12) .
MUC2 and MUC6 genes are located at 11p15.5, in a recombination-rich region containing a 400 kb gene cluster which also contains two other mucin genes (MUC5AC and MUC5B). Their 5# region is highly similar and is clearly differentiated from the 3# region by a large central tandem repeat (TR) domain, which is in exon 30 in MUC2 and in exon 31 in MUC6. In contrast, the C-terminal domain is encoded by 19 exons in MUC2 and only 2 exons in MUC6 (13) . MUC1 localizes in 1q21 and it is a smaller gene with its TR region in exon 2. Some studies have addressed the role of genetic polymorphisms in mucosal protection genes but most of them have been focused on the serine and threonine-rich VNTR (variable number of TRs), characteristic of the MUC genes (14) (15) (16) (17) (18) (19) (20) . More recently, a functional single-nucleotide polymorphism (SNP) (rs4072037) in MUC1 has been strongly associated with gastric cancer in Asian populations (21) (22) (23) . However, none of these studies have assessed how these inherited genetic variants predispose to progression or regression of premalignant lesions of the stomach, although MUCs have been long implicated in the pathogenesis of gastric carcinogenesis (4, 9) .
In the present study, we have used comprehensive genetic markers that capture the most common variability at each locus to analyze the constitutional genetic variability of MUC1 (gene ID: 4582), MUC2 (gene ID: 4583) and MUC6 (gene ID: 4588) genes and to assess its relationship with the evolution of gastric cancer precursor lesions (GCPLs) after a long-term follow-up in a Spanish region with one of the highest incidence and mortality from gastric cancer.
Methods

Study population
The study population for association with the evolution of GCPLs consisted of 478 subjects from a follow-up study described in detail previously (24) . Briefly, patients with GCPLs were identified from the Pathology Department Registry of the Soria Hospital as having undergone gastroscopy with gastric biopsy between 1988 and 1994. Patients were followed up until 2005-2007 (12.8 years of mean follow-up) when a new gastroscopy with biopsy was performed. Genomic DNA, either from blood (n 5 417) or from paraffin-embedded tissue blocks when blood sampling was not possible (n 5 36), was obtained from 453 (95%) patients. Sixty-six samples had to be excluded from this study because their DNA did not fulfill the minimum criteria required for genotyping in the Sequenom platform. The specific study population for genetic analysis was therefore of 387 patients with GCPLs (Table I) .
Gastric lesions were classified, at recruitment and at the end of follow-up, as: 1 5 normal, 2 5 non-atrophic gastritis, 3 5 non-metaplastic multifocal atrophic gastritis, 4 5 complete intestinal metaplasia (IM, including predominant complete IM), 5 5 incomplete IM (including predominant incomplete IM), 6 5 dysplasia and 7 5 gastric cancer. Based on the diagnosis at recruitment and at the end of follow-up, it was considered that the lesions had progressed or regressed if they had respectively advanced or regressed at least one point of in the overall score (1 to 7). The lesions were considered to be stable if they maintained the same score.
Abbreviations: CI, confidence interval; GCPL, gastric cancer precursor lesion; IM, intestinal metaplasia; LD, linkage disequilibrium; NAG, nonatrophic gastritis; NSAID, non-steroidal anti-inflammatory drug; MAG, multifocal atrophic gastritis; OR, odds ratio; SNP, single-nucleotide polymorphism; TR, tandem repeat.
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DNA extraction
Genomic DNA from blood samples was extracted from lymphocytes by use of the Flexigene DNA kit (Qiagen), according to the manufacturer's instructions. Paraffin-embedded tissue blocks were cut into 10 sections of 10 lm and deparaffinized in xylene. Genomic DNA extraction from the deparaffinized tissue was carried out using the QIAamp DNA Mini Kit (Qiagen). DNA concentrations were measured by optical density at 260 nm on a NanoDrop ND-1000 (Thermo Scientifics) spectrophotometer and stored at À80°C in 96-well plates at a concentration $100 ng/ll.
SNP selection criteria
We selected tagSNPs from the 1q21 genomic region containing MUC1 gene and from the mucin cluster in 11p15, which contains MUC2 and MUC6 genes. We used HapMap information for Caucasians [phase II CEU population, release 24, where CEU refers to CEPH (Utah residents with ancestry from northern and western Europe) population] to compile a list of SNPs from a minimum of 7 kb upstream to 3 kb downstream of each of the MUC genes. Unfortunately, due to absence of HapMap information for most of the MUC5AC gene, which also locates in the same cluster region, this gene could not be analyzed. Haplotype blocks were defined by use of the confidence intervals (CIs) method of Gabriel et al. (25) , as implemented in Haploview v4.0 software (26) . Tagging SNPs were selected by use of the Tagger algorithm as implemented in Haploview. Parameters used for tagSNPs selection were minor allele frequency !5% in Caucasians, r 2 !0.8 between each pair of tagged and tagging SNPs (pairwise tagging) and SNPs tagging haplotypes with a frequency !0.05. Validated potentially functional SNPs replaced tagger selected tagSNPs only if they were in complete linkage disequilibrium (LD) with them.
Following these criteria, we defined two haplotype blocks spanning 51 kb in the 1q21 genomic region containing MUC1 (4.4 kb) and part of TRIM46 gene (at 855 bp 3#-downstream of MUC1) and we selected four tagSNPs, two for each block. In chromosome region 11p15, we defined a 29 kb haplotype block that included MUC6 (23.9 kb) and was tagged by six tagSNPs. Also in 11p15, in the 47 kb genomic region that includes MUC2 (29.5 kb), we defined seven haplotype blocks and 15 tagSNPs (Figure 1 ). Table II shows the main characteristics and location of all selected SNPs.
SNP genotyping and data filtering
The set of 25 tagSNPs selected in MUC1, MUC2 and MUC6 genes (Table II) were genotyped using the MassArray TM iPlex-Gold technology (Sequenom) at the National Genotyping Center of Spain (CEGEN), in a customized assay design. In addition to the internal genotyping controls included by CEGEN, 17 samples (4.4%) chosen randomly were genotyped in duplicate for all tagSNPs to assess the genotyping error rate. Concordance of their genotypes was complete in all cases and no genotyping errors were observed. From the 25 SNPs initially selected, 3 were excluded (Table II) because they could not be amplified or their genotyping signal or cluster separation was not good enough. The total number of SNPs successfully genotyped and available for analysis was therefore 22. None of these SNPs deviated from Hardy-Weinberg equilibrium in the total analyzed population (chi-square test P . 10 À3-; Table II ). The average call rate of the analyzed SNPs was 98% and none of them had a call rate ,80%.
Helicobacter pylori infection diagnosis
Helicobacter pylori infection was detected by histopathological examination of Giemsa-stained biopsies. Infection status was also identified by reviewing the medical records (results from rapid urease test on biopsy specimen and urea breath test) and interviewing subjects about previous prevalence of H.pylori. Finally, DNA was isolated from paraffin-embedded tissue blocks from available gastric biopsies (n 5 312) and H.pylori detection and strain characterization was carried out as described previously (27) . A positive result for any of these tests was taken as a positive H.pylori infection in the analyzed patient.
Association analyses
The Pearson v 2 test was used to examine differences among the GCPLs evolution groups according to the main baseline characteristics of the population. In order to capture all the variability associated with the evolution of lesions, two type of analyses were performed (i) in the analysis of lesion progression, the group of patients whose lesions progressed were compared with those whose lesions remained stable or regressed (reference group); (ii) in the analysis of lesion regression, those patients whose lesions regressed where compared with those whose lesions remained stable or progressed. Odds ratios (OR) and 95% CIs were estimated using unconditional logistic regression, as 
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implemented in SNPassoc R library software (28) . Final models included sex, age, non-steroidal anti-inflammatory drugs (NSAID) consumption and type of lesion at recruitment, as covariables for adjustment. All analyses were done under codominant, dominant, recessive and log-additive (per allele) inheritance models. Stratified analyses were carried out according to H.pylori infection and NSAID consumption. Potential interactions between the SNP of interest and H.pylori status or NSAID consumption were assessed by means of the likelihood ratio test. LD between polymorphisms in each MUC gene region was explored with the Haploview software and haplotype frequencies were inferred using the expectation-maximization algorithm as implemented in the haplo.stats R package. Association between progression or regression and each MUC haplotype Table 2 , for MUC2 SNPs, from top to bottom. The position and exon-intron structure of MUC2, in this region, is also indicated. with a frequency .0.01 was measured using the most frequent haplotype among controls as reference.
Results
Evolution of the lesions was assessed based on the diagnosis at recruitment and at the end of the follow-up. We identified 167 patients (43.1%) whose lesions did not change, 111 (28.7%) regressed and 109 (28.2%) progressed. The main characteristics of the analyzed population (n 5 387) are shown in Table I . The use of NSAIDs was protective against lesion progression (OR 5 0.57, 95% CI: 0.34-0.87, P 5 0.01).
MUC genes genotype frequencies and association with evolution of the lesions The total number of SNPs successfully genotyped and available for analysis was 22. Of these, 3 localized in MUC1, 5 in MUC6 and 14 in MUC2 genomic regions. Table II shows their minor allele frequencies in the total population and in each evolution group. No significant association was observed between evolution of the GCPLs and the genotyped variants in MUC1 and MUC6 genes (data not shown). On the other hand, as shown in Table III , three SNPs in MUC2, rs10794293 in intron 37 and rs3924453 and rs4077759 in 3#-downstream from the gene, associated with a decreased risk of progression of the lesions. The A allele of rs3924453 and the C allele of rs4077759 appeared as protective factors for progression of the lesions and this effect was significant under the log-additive and recessive inheritance models, as well as the codominant model for rs4077759. Both SNPs tagged a 4 kb haplotype block containing the 3# end and downstream region of MUC2 (Figure 1 ). The T allele of rs10794293 in intron 37 was also associated with a decreased risk of progression under the log-additive and dominant inheritance models. This SNP tags a haplotype block also downstream from the central TR region of the gene.
As shown in Table IV , another four MUC2 SNPs located at the central and 5# region of the gene (rs10902073, rs10794281, rs2071174 and rs7944723) were found to be significantly associated with regression of the lesions. SNPs rs10902073 and rs10794281, which tag the main MUC2 7 kb haplotype block at 5#-upstream of the gene, were associated with a reduced probability of regression under the log-additive and dominant models. A significant association with less regression was also observed for rs7944723, a synonymous coding SNP in central exon 30, under the recessive model. On the other hand, the C allele of rs2071174, located at 5#-upstream of MUC2 and tagging the haplotype block that contains the promoter region and the first exons of the gene, was associated with an increased probability of regression of the lesions, under the codominant and recessive models. Altogether, our results point to a protective effect of SNPs at MUC2 during evolution of GCPLs.
Effect modification by Helicobacter pylori
When the effect of those MUC2 SNPs significantly associated with the evolution of the GCPLs was analyzed according to H.pylori infection, it was seen that in all cases the association was significant only in those subjects positive for the infection (Tables III and IV) , being the interaction statistically significant for rs4077759, under the codominant and recessive models (Table III) , as well as for rs10902073 and rs10794281, under the log-additive, dominant and codominant models (Table IV) .
Effect modification by consumption of NSAIDs When the effect of those MUC2 SNPs significantly associated with the evolution of the GCPLs was analyzed according to consumption of NSAIDs, it was seen that all SNPs but rs10902073 and rs7944723 were significantly associated with the evolution of the lesions in non-NSAID users, but not in users, and that in all cases, the association was in agreement with the one observed with the non-stratified analyses (data not shown), but no interaction was observed between these MUC2 variants and NSAIDs consumption.
Mucin haplotypes and evolution of lesions
Measures of LD (r 2 and D#) between the analyzed SNPs in the mucin genes were in good agreement with those measured in HapMap for Caucasians (data not shown). In the same way, haplotype analysis showed similar results to those observed in HapMap from Caucasians.
Regarding MUC2 gene, haplotype analysis was performed separately in the 5# and 3# regions. Six SNPs were located from central exon 30 to the 5# region and tagged 10 different haplotypes with frequencies between 0.345 and 0.014. Eight SNPs were located in 3#-half region of the gene and these tagged another 10 haplotypes with frequencies between 0.322 and 0.018 (Table V) . The haplotype CTCCCG, at the 5# region, was significantly associated with a decreased risk of progression of the lesions as well as an increased probability of regression (Table V) . This haplotype carried the minor allele (C) of rs2071174 that had also been found associated with an increased probability of regression and the two common alleles of SNPs rs10902073 (C/A) and rs10794281 (T/C) whose variant alleles associated with a reduced probability of regression in the individual SNP analysis. In the 3# region, haplotype CATAGAAC also was associated with a decreased risk of progression (Table V) . This haplotype carried the three alleles (T, A and C of rs10794293, rs3924453 and rs4077759, respectively) that had also been found associated with a decreased risk of progression in individual SNP analysis. The haplotype resulting from the combination of these two significant haplotypes in the 5# and 3# regions (CTCCCGCATAGAAC, with a frequency of 0.120) also showed a trend as protector for progression (OR 5 0.53, 95% CI: 0.26-1.07, P 5 0.075) when compared with the ACCTCGCGCAAAGT (frequency of 0.147), although it did not reach statistical significance (results not shown).
As expected, no significant association with progression or regression of the GCPLs was found with the six inferred MUC1 haplotypes with frequencies between 0.01 and 0.46 and with the six inferred MUC6 haplotypes with frequencies between 0.06 and 0.37.
Discussion
In this study, we have assessed whether genetic variability in three genes (MUC1, MUC2 and MUC6) involved in the mucosal protection associates with the evolution, either progression or regression, of GCPLs after a mean follow-up of 12.8 years in a region with one of the highest incidence of and mortality from GC in Spain and Western Europe (24) . The major novel finding is that variability in MUC2 gene is protective regarding the evolution of GCPLs and this effect is more evident in H.pylori-infected patients and in those not consuming NSAIDs.
MUC2 is the major constituent of the secreted mucus barrier in the small and large intestines, where it is mainly produced by goblet cells (29, 30) . A number of reports have provided evidence on the role of MUC2 in maintaining the integrity of the protective mucus layer in intestine and reduced MUC2 expression has been related to inflammation and development of several intestinal diseases, including cancer (3, 9, 30, 31) . In contrast, MUC2, which is not normally expressed in stomach, is present at increased levels in intestinal metaplasia and in gastric adenocarcinoma (5) (6) (7) 32, 33) . It has been reported that MUC2 overexpression might be the consequence of its activation by proinflammatory cytokines expressed after H.pylori infection (33) . MUC2 overexpression may also reflect the stomach transformation during intestinal metaplasia into an intestinal-type epithelium in which glandular gastric cells are replaced by goblet cells. With regard to its role in gastric carcinogenesis, it has been suggested that MUC2 might contribute to malignant phenotype by protecting against recognition by antitumor immune effectors (9) . Therefore, genetic variation in the MUC2 gene that would modify its expression or biological activity could result in an altered pathway toward gastric carcinogenesis. Only one study has recently assessed the association between Mucin gene variants and evolution of GCPLs Unconditional logistic regression analysis, adjusted for sex, age, NSAID consumption and lesion at recruitment. candidate SNPs in MUC2, as well as in MUC5B, MUC6 and MUC1, with the risk of chronic atrophic gastritis, a specific GCPL, but no association was identified (34) . Interestingly, polymorphisms associated with regression of the GCPLs were located from the central to the 5#-upstream genomic region of the gene, whereas polymorphisms associated with progression were located in the 3# and downstream region. When haplotype analyses were carried out, it was observed that the CTCCCG haplotype in the 5# region of the gene was associated with regression of the GCPLs and, in agreement with it, it also had a protective role against progression of the lesions. Furthermore, the CATAGAAC haplotype in the central and 3# region of the gene was also significantly associated with a decreased risk of progression of the lesions, thereby also indicating a protective role of this haplotype against progression. Finally, when the haplotype analysis was done with all MUC2 SNPs, it was observed that the CTCCCGCATAGAAC haplotype, which combines the 5# and 3# protective haplotypes, also shows a clear although not significant tendency toward protection against progression of the GCPLs. All these results suggest that either the combination of different genetic variants in the gene or the effect of a yet an unknown variant in LD with the analyzed ones in each side of the central gene region modify the capacity of the lesions to progress toward gastric carcinoma.
Our results do not inform on the nature of the functional variant/s responsible for the observed associations. Nevertheless, since we used a tagSNP genotyping strategy, it is likely that the causative variants are in strong LD with the genotyped and significant ones. Although functional studies and association analyses with expression levels should be performed to analyze the causal relationships between the associated variants and gastric carcinogenesis, several lines of evidence indicate that this relationship might exist. Thus, rs10902073 and rs10794281 tag a strong LD block in the genomic region 5#-upstream of MUC2, suggesting that the variant responsible for increased probability of regression might be present in the upstream regulatory sequences of the gene expression. Rs2071174, which was associated with an increased probability of regression, tags a common non-synonymous Val116Met SNP (rs11825977) that has been suggested to be responsible for significant downregulation of MUC2 in Crohn's disease, due to reduced messenger RNA expression (35) .
Rs7944723, locates at the end of central exon 30, which encodes for the highly polymorphic TR region, with properties essential to the surface epithelial protective function of mucins (8) . This SNP, together with rs10794293 and rs6421972, tags a 5 kb haplotype block in 3# region of the gene that corresponds to C-terminus domain containing an autocatalytic proteolytic cleavage site predicted to cause disassembly of MUC2 polymers and to affect the mucus viscosity (36, 37) . Finally, rs4077759 and rs3924453 are tags of a 4 kb haplotype block containing the last exons of the gene and the 3#downstream genomic region where there are other potentially functional variants in the region, such as some missense coding SNPs and 3#-UTR variants. It is interesting to note that we have not found association with any of the MUC2 missense SNPs analyzed (Table II) , which could be indicative of association being more probably due to variants that regulate MUC2 expression.
The effect of all associated SNPs with GCPLs was found to be stronger and only significant in H.pylori-infected patients, being the interaction statistically significant for rs10902073, rs10794281 and rs4077759. Despite the relative low number of patients negative for H.pylori infection (23%) and the consequent statistical power limitations, the calculated ORs do not follow the same trend in infected and non-infected patients, suggesting a real interaction between gene variability and infection by the bacteria in the evolution of the lesions. Although a physical interaction between H.pylori and MUC2 has not been established, the importance of this secreted mucin in bacterial colonization and infection by pathogens has been broadly demonstrated in the intestine (31, 38) . In stomach, H.pylori infection has been reported to cause an aberrant expression of MUC2 gene in gastric carcinoma cells (39) . Moreover, ectopic expression of MUC2 has been associated with the induction of CDX1 by cagA strain of H.pylori in gastric epithelial cells that have been arrested in G1 (40) . Therefore, although we do not know the precise molecular mechanism by which variation in MUC2 may interact with H.pylori infection to influence the evolution of GCPLs, the fact that the infection associates with aberrant expression of MUC2 and that, as stated in the above paragraph, genetic variants of MUC2 may influence its expression or protein function, provide biological support to the joint effect of these two factors. In contrast, although our results show that the effect of these MUC2 variants on the evolution of the lesions is significant only in non-NSAID users, no interaction was found between both factors. Given the protective effect of NSAID consumption on the progression of the lesions observed in this study, it seems that the protective effect of genetic variation in MUC2 is more clearly observed in those patients not already protected by NSAID consumption. Strengths of this study are the long and well-defined follow-up and its relatively large size that allowed us to evaluate the risk for progression and regression of lesions conferred by genetic variants in MUC genes. To our knowledge, only one study has analyzed the association between genetic variability (in DNA repair genes in this case) with evolution of GCPLs, also with the identification of some significant associations (41) . Among the weaknesses, it is to mention that although the sample size is relative large considering the characteristics of the follow up, it was not large enough to avoid power limitations to detect other potential associations with some of the analyzed SNPs and genes, such us MUC1 and MUC6. Furthermore, failure in the genotyping of three of the selected tagSNPs, among which MUC1 rs4072037 that has recently been found associated with gastric cancer (21) (22) (23) , has reduced the coverage of the genetic variability of these genes by 40% in the case of MUC1, but only ,10% of MUC2 and MUC6. Therefore, additional genotyping and association analyses in a larger sample series are needed to comprehensively elucidate and confirm the role in the gastric carcinogenesis pathway of genetic variability in the mucin genes, as well as their interaction with other risk factors such as infection by H.pylori.
In conclusion, this is the first study to address the association of mucin gene variants with progression and regression of precursor lesions of gastric cancer. Our analysis has provided evidence that genetic polymorphisms in MUC2 gene are associated with evolution of GCPLs, especially in H.pylori-infected patients, suggesting an important role of this secreted mucin in gastric carcinogenesis.
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